Evidence map›Paper›PMID 36881785›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.

Jieyun Xia, Hujun Li, Zhiling Yan, Dian Zhou, Ying Wang, Yuekun Qi, Jiang Cao, Depeng Li, Hai Cheng, Wei Sang and 17 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
19.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 2 institutions in 1 country.

Jieyun XiaBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Hujun LiBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Zhiling YanBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Dian ZhouBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Ying WangBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Yuekun QiBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0003-4431-3060
Jiang CaoBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0003-3767-9283
Depeng LiBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Hai ChengBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Wei SangBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Feng ZhuBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0002-9356-2154
Haiying SunBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Wei ChenBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0001-5480-6577
Kunming QiBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Dongmei YanBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Tingting QiuBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Jianlin QiaoBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0002-0456-0940
Ruosi YaoBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Yang LiuBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Xue WangBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.
Yanlei ZhangShanghai YaKe Biotechnology Ltd, Shanghai, China.ORCID 0000-0002-7658-7691
Shuixiu PengShanghai YaKe Biotechnology Ltd, Shanghai, China.
Chih-Hua HuangShanghai YaKe Biotechnology Ltd, Shanghai, China.
Junnian ZhengCancer Institute, Xuzhou Medical University, Xuzhou, China.
Zhenyu LiBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0003-4610-9135
Alex H ChangShanghai YaKe Biotechnology Ltd, Shanghai, China.ORCID 0000-0002-7572-309X
Kailin XuBlood Diseases Institute, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0003-1375-1084
Xuzhou Medical College · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeG protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.

methodsThis phase Ⅱ, single-arm study enrolled patients (18-70 years) with R/R MM. Lymphodepletion was performed before patients received 2 × 10

resultsFrom September 1, 2021, to March 23, 2022, 33 patients were infused with anti-GPRC5D CAR T cells. At a median follow-up of 5.2 months (range, 3.2-8.9), the overall response rate was 91% (95% CI, 76 to 98; 30 of 33 patients), including 11 (33%) stringent complete responses, 10 (30%) complete responses, four (12%) very good partial responses, and five (15%) partial responses. Partial responses or better were observed in nine (100%) of nine patients with previous anti-B-cell maturation antigen (BCMA) CAR T-cell therapy, including two patients who had received repeated anti-BCMA CAR T-cell infusions with no responses at the last time. Grade 3 or higher hematologic toxicities were neutropenia (33 [100%]), anemia (17 [52%]), and thrombocytopenia (15 [45%]). Cytokine release syndrome occurred in 25 (76%) of 33 patients (all were grade 1 or 2), and neurotoxicities in three patients (one grade 2 and one grade 3 ICANSs and one grade 3 headache).

conclusionAnti-GPRC5D CAR T-cell therapy showed an encouraging clinical efficacy and manageable safety profile in patients with R/R MM. For patients with MM that progressed after anti-BCMA CAR T-cell therapy or that is refractory to anti-BCMA CAR T cell, anti-GPRC5D CAR T-cell therapy might be a potential alternative option.

Indexed as

AnemiaMultiple MyelomaReceptors, Chimeric AntigenAdolescentAdultAgedAntibodiesHumansImmunotherapy, AdoptiveMiddle AgedT-LymphocytesTreatment OutcomeYoung AdultAntibodiesReceptors, Chimeric Antigen

Identifiers

PMID36881785
PMCPMC10414745
OpenAlexW4323351721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.